Resources for News Media
The NCI press office is the central news contact for all members of the media. The office can assist you in arranging interviews with NCI researchers and in providing accurate and timely cancer research news and information.
For information about NCI's history and current activities, see NCI Overview and Budget and Appropriations.
Connect with Us
Our office hours are Monday through Friday, 9 a.m. to 5 p.m. ET.
Email: ncipressofficers@mail.nih.gov
Phone: 240-760-6600
Social Media:
@NCIMedia
NCI's YouTube Channel
Address:
Building 31, Room 10A25
31 Center Drive MSC 2580
Bethesda, MD 20892-2580
Recent Interviews from Scientists at NCI
-
Action Needed to Hit 'Moonshot' Goal of Halving Cancer Deaths by Mid-Century
April 17, 2023 | HealthDay
The United States will fall short of its Cancer Moonshot goal of cutting cancer deaths by at least half over the next 25 years unless more action is taken, a new U.S. National Cancer Institute analysis concludes. -
Lung Cancer Trial Has Broader Eligibility Criteria, Overcomes Barriers
April 14, 2023 | CURE
The National Cancer Institute (NCI) launched the phase 3 Pragmatica-Lung Study (S2302) clinical trial evaluating Cyramza (ramucirumab) plus Keytruda (pembrolizumab) for patients with stage 3 or recurrent non-small cell lung cancer, according to a press release from the agency. -
How the cloud is letting the National Cancer Institute take the IT burden off its mission areas
March 31, 2023 | Federal News Network
The National Cancer Institute is keeping its IT modernization strategy pretty simple. There is cloud one and there is cloud two. All new development will reside in one of those two instances. -
The Cancer Moonshot Enters a New Phase
January 25, 2023 | IEEE Pulse
Moonshot-supported research has made progress in lowering cancer mortality rates, and this new initiative prioritizes diversity in research with a goal of ending cancer as we know it -
Drug Approved to Help Young Patients Battle a Rare Cancer
January 2, 2023 | HealthDay
Children and adults with a rare type of soft tissue cancer will now have a new treatment option that could have a big impact. The U.S. Food and Drug Administration has approved the immunotherapy drug atezolizumab (Tecentriq) for use in patients with advanced alveolar soft part sarcoma (ASPS) that has spread to other parts of the body or cannot be removed by surgery. -
Telehealth For Cancer Care Receives $23 Million Research Funding Boost
August 18, 2022 | Forbes
The National Cancer Institute at the National Institutes of Health (NIH) will award funding to conduct research into the use of telehealth for cancer care by creating four new “Telehealth Research Centers of Excellence.” -
Drinking Black Tea May Lower Mortality Risk, Study Suggests
August 29, 2022 | Time
While green tea has a long-standing reputation for health benefits, research has been much more mixed on black tea. One problem, says Maki Inoue-Choi, an epidemiologist at the National Cancer Institute, is that large observational studies on tea and mortality have focused on countries like Japan or China—places where green tea is more popular. -
'We still are dying at alarming rates': Black cancer death rates are falling but remain higher than others, study finds
May 19, 2022 | USA Today
Despite declining cancer death rates, Black people still died of cancer at higher rates than any other racial group, a new study shows.
Trending Topics
-
National Cancer Plan - Join Us
People across the country and worldwide are counting on us to end cancer as we know it. Research alone will not accomplish this. To succeed, we must work together to develop strategies, share knowledge, and accelerate progress. The National Cancer Plan provides a comprehensive framework for this meaningful collaboration and unites us in acting on the vision President Biden and First Lady Biden set out in the Cancer Moonshot℠ to end cancer as we know it.
-
Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry
Article on ScienceDirect - Background: Genetic factors play an important role in prostate cancer (PCa) susceptibility; Objective: To discover common genetic variants contributing to the risk of PCa in men of African ancestry.
-
White House Fact Sheet: On One Year Anniversary of Reignited Cancer Moonshot, Biden-Harris Administration Announces New Actions to End Cancer as We Know It
One year ago, President Joe Biden and First Lady Jill Biden reignited the Cancer Moonshot, setting an ambitious, achievable goal: to reduce the death rate from cancer by at least 50 percent over the next 25 years, and improve the experience of people and families living with and surviving cancer, ultimately ending cancer as we know it today.
-
HER2’s Genetic Link to Breast Cancer Spurs Development of New Treatments
HER2 is a gene that has been linked to breast cancer growth. Learn about the development of trastuzumab, a monoclonal antibody that blocks the HER2 protein, and other treatments that have improved survival for women with HER2-positive breast cancer.
-
Breast Cancer—Patient Version
Breast cancer is the second most common cancer in women after skin cancer. Mammograms can detect breast cancer early, possibly before it has spread. Start here to find information on breast cancer treatment, causes and prevention, screening, research, and statistics.
-
Uterine Cancer—Patient Version
Uterine cancers can be of two types: endometrial cancer (common) and uterine sarcoma (rare). Endometrial cancer can often be cured. Uterine sarcoma is often more aggressive and harder to treat. Start here to find information on uterine cancer treatment, causes and prevention, screening, research, and statistics.
-
Cancer Treatment Vaccines
Cancer treatment vaccines treat cancer by strengthening the body’s natural defenses against the cancer. This page covers how cancer treatment vaccines work against cancer, cancers that are treated with them, and the side effects they may cause.
-
Cancer death rates among Black people declined over time, but remain higher than other racial and ethnic groups
From 1999—2019, US rates of cancer death fell among Black people. Yet, in 2019, their rates remained higher than those of other racial and ethnic groups.
-
NCI COVID-19 in Cancer Patients Study (NCCAPS)
The NCI COVID-19 in Cancer Patients Study, or NCCAPS, is a natural history study of COVID-19 in people with cancer. The knowledge gained from this study will help doctors better manage treatment for people with cancer and COVID-19 in the future.
Multimedia from NCI
50 Years of Cancer Treatment and Diagnostics
Clinical trials, innovation in research, and technology have improved cancer treatment and diagnostics in public health. Listen to Healthcast’s National Cancer Act podcast series to learn more.
Recent News Releases
-
NCI’s ComboMATCH initiative will test new drug combinations guided by tumor biology
ComboMATCH will consist of numerous phase 2 cancer treatment trials that aim to identify promising drug combinations that can advance to larger, more definitive clinical trials.
-
NCI study outlines opportunities to achieve President Biden’s Cancer Moonshot goal of reducing cancer death rates in the United States
A new study has outlined opportunities for achieving President Biden and First Lady Biden’s Cancer Moonshot goal of reducing the cancer death rate by at least 50% over the next 25 years.
-
Pragmatica-Lung Study, a streamlined model for future cancer clinical trials, begins enrolling patients
NCI has helped launch the Pragmatica-Lung Study, a phase 3 randomized clinical trial of a two-drug combination to treat patients with advanced non-small cell lung cancer. The simplified trial design aims to increase accessibility for participants.